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BACKGROUND: The objectives of this study were to evaluate survival among current smokers, former smokers, and never smokers
who are diagnosed with non–small cell lung cancer (NSCLC). METHODS: The study included patients who participated in the National
Comprehensive Cancer Network’s NSCLC Database Project. Current, former, and never smokers were compared with respect to over-
all survival by fitting Cox regression models. RESULTS: Data from 4200 patients were examined, including 618 never smokers, 1483
current smokers, 380 former smokers who quit 1 to 12 months before diagnosis, and 1719 former smokers who quit >12 months before
diagnosis. Among patients with stage I, II, and III disease, only never smokers had better survival than current smokers (hazard ratio,
0.47 [95% confidence interval, 0.26-0.85] vs 0.51 [95% confidence interval, 0.38-0.68], respectively). Among patients with stage IV
disease, the impact of smoking depended on age: Among younger patients (aged 55 years), being a never smoker and a former
smoker for 12 months increased survival. After age 85 years, smoking status did not have a significant impact on overall survival.
CONCLUSIONS: Patients who were smoking at the time of diagnosis had worse survival compared with never smokers. Among
younger patients with stage IV disease, current smokers also had worse survival compared with former smokers who quit >12 months
before diagnosis. It is likely that tumor biology plays a major role in the differences observed; however, to improve survival, it is
prudent to encourage all smokers to quit smoking if they are diagnosed with NSCLC. Cancer 2013;119:847-53. VC 2012 American
Cancer Society.
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INTRODUCTION
There is a growing body of literature that links smoking with poor outcomes among patients with lung cancer. A recent
meta-analysis estimated that individuals who continued to smoke and were diagnosed with early stage non–small cell lung
cancer (NSCLC) had 2.94 times the risk of mortality (95% confidence interval, 1.15-7.54) compared with those who quit
at diagnosis.1 The meta-analysis results also suggested that smokers with small cell lung cancer are at increased risk of mor-
tality if they continue to smoke. It has been observed that smoking after a diagnosis of lung cancer decreases performance
status,2 increases the risk of a second primary tumor,3-5 and increases the risk of complications from radiation therapy.6
Quitting smoking before lung cancer surgery has been the topic of at least 2 reports. Mason and colleagues examined
data from the Society of Thoracic Surgeons General Thoracic Surgery Database and observed that mortality and compli-
cations were increased among continued smokers and decreased with increasing time since cessation.7 Erhunmwunsee
and Onaitis reviewed the literature on smoking and lung cancer surgery outcomes and concluded that smoking increases
the likelihood of surgical complication rates and that smoking cessation can improve outcomes.8 A recent study suggests
that smokers who quit between diagnosis and surgery are more likely to return to normal functioning after surgery than
smokers who do not quit after diagnosis.9
Not all studies have concluded that smoking decreases survival among patients with NSCLC.Meguid and colleagues
compared current smokers versus never smokers with respect to mortality in a sample of greater than 4500 patients with
NSCLC and observed no difference in survival.10 Similarly, Toh and coauthors reported no difference between current
smokers and never smokers in their sample of 317 patients from Singapore.11
Molecular analyses of lung tumor samples in the last decade have demonstrated that particular molecular ‘‘driver
mutations’’ are more common in never-smoking patients who have lung cancer compared with patients who have a heavy
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smoking history.12,13 Defining these molecularly charac-
terized subtypes is incredibly important in the choice of
therapeutic options for patients with advanced or meta-
static disease, although there is less evidence to date that
choice of therapy should be altered according to molecular
classification for patients with earlier stage disease (stages
I-III). The impact of these molecular differences on prog-
nosis, however, is somewhat more mixed. For example,
although patients who have epidermal growth factor re-
ceptor (EGFR) mutations (an estimated 40%-60% of
never smokers with lung cancer) may have a better prog-
nosis than patients without EGFR mutations,14 it has
recently been suggested that patients who have anaplastic
lymphoma kinase (ALK) translocations (which also are
observed more frequently in never smokers) do not bear
an improved prognosis (absent treatment with the appro-
priate tyrosine kinase inhibitor).15
The National Comprehensive Cancer Network
(NCCN) is a multisite network with 21 cancer centers
covering nearly every region of the United States. The
NCCN NSCLC Database Project, which was established
in 2008, contains clinical and treatment information on
eligible patients with NSCLC from 8 NCCN sites. We
used data from the NCCN NSCLC Database Project to
compare survival among current, former, and never smok-
ers who were diagnosed with NSCLC.
MATERIALS AND METHODS
Participants
The study cohort consisted of patients who presented to 1
of the 8 NCCN member institutions participating in the
NSCLC Database Project through December 2011. The
NCCN sites include the following cancer centers: City of
Hope, Duarte, Calif; Duke Cancer Institute, Durham,
NC; The Sidney Kimmel Comprehensive Cancer Center
at Johns Hopkins, Baltimore,Md; TheUniversity ofMich-
igan Comprehensive Cancer Center, Ann Arbor, Mich;
The University of Texas M. D. Anderson Cancer Center,
Houston, Tex; Roswell Park Cancer Institute, Buffalo, NY;
and The Ohio State University Comprehensive Cancer
Center-James Cancer Hospital and Solove Research Insti-
tute, Columbus, Ohio. Patients with a recent diagnosis of
NSCLC (within the past 6 months) are included in the
database. Patients were excluded from the analysis if they
had 1 or more of the following: 1) presented with a nonre-
cent NSCLC diagnosis (>180 days ago); 2) had incom-
plete baseline data, including demographic, medical
history, or smoking status data; 3) had incomplete staging;
4) had a past diagnosis of cancer; or 5) had <180 days of
follow-up, unless they died within 180 days.
Measures
All data were collected from medical record review and
abstraction. A database manager/cancer registrar from
each participating site abstracted data from patient
records and entered these data into a deidentified central
database maintained at the data Coordinating Center
located at City of Hope in Duarte, Calif.
The primary independent variable was smoking sta-
tus at diagnosis. The 4 categories that were used for this
analysis were: 1) never smoker, 2) former smoker for 1 to
12 months before diagnosis, 3) former smoker for >12
months before diagnosis, and 4) current smoker. Smokers
who had 10 pack-years of smoking were excluded from
the former and current smoker groups because of their
small sample size (n¼ 250) in the cohort. Other variables
of interest were stage of disease (stage I and II combined,
stage III, or stage IV), histology (squamous cell, adenocar-
cinoma and bronchioloalveolar [BAC], or other), age at
diagnosis, sex, race (white or other), Charlson comorbid-
ity score16 (0 vs 1), receipt of drug therapy (chemother-
apy and targeted therapy), receipt of radiation therapy,
receipt of surgery, performance status, and NCCN insti-
tution. Patients with stage I and II disease were combined
into 1 group, because these stages represent localized dis-
ease that are treated primarily with surgical resection, with
our without adjuvant chemotherapy. In addition, the
number of patients with stage II disease was small, which
would have made comparisons by smoking status within
the group of stage II patients difficult.
The outcome of interest was death from any cause
during the follow-up period. Follow-up for survival analy-
sis was defined as the time in years from tumor diagnosis
to the date of death from any cause or last known vital sta-
tus date.
Statistical Analysis
Descriptive statistics, including the mean and standard
deviation for continuous variables and frequency distribu-
tions for categorical variables, were calculated according
to smoking status category. Two-year survival and
Kaplan-Meier survival curves were estimated for each
smoking group. Stage-specific Cox proportional hazards
models were used to examine the association between sur-
vival and smoking status after testing the proportionality
assumption and adjusting for potential significant con-
founders. Hazard ratios (HRs) and 95% confidence inter-
vals (CI) were estimated for each smoking group using
current smokers as the reference group. In addition, sensi-
tivity analyses were performed to determine whether the
minimum 180-day follow-up rule had an impact on the
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results, and these analyses did not reveal any substantial
influence of this inclusion criterion.
To build the final adjusted multivariable Cox pro-
portional hazards models, the effect of each of the follow-
ing 10 potential confounding variables on the survival of
different smoking groups was evaluated: age, NCCN
institution, sex, race, Charlson comorbidity score, Eastern
Cooperative Oncology Group performance status, histol-
ogy, receipt of drug therapy, receipt of radiation therapy,
and receipt of resection. The approach to model building
involved adding only variables that altered the coefficients
for smoking status by 20% rather than adding all varia-
bles that significantly predicted survival. Hence, we did
not build a ‘‘prediction’’ model, because the objective was
to determine the unconfounded association between
smoking status and survival. The interaction effects of
smoking status with age and with sex also were evaluated
in all final multivariable models.
The functional form of age was tested using cumula-
tive martingale residual plots. Because the test revealed a
linear relation, age at diagnosis was used as continuous
variable in all models. Proportional hazards assumptions
were evaluated for each variable in the final models by
examining Schoenfeld residuals and by fitting interaction
terms of each covariate with time in the final model. Over-
all goodness-of-fit was established using likelihood ratio
tests. All final models met proportional hazards assump-
tions, achieved good fit, and converged according to like-
lihood ratio tests. All statistical analyses were performed
using the SAS statistical software package (version 9.3;
SAS Institute Inc., Cary, NC).
RESULTS
In total, 6361 newly diagnosed patients were accrued to
the database between January 2007 and December 2011.
Patients were eliminated from the cohort if they had a
past history of cancer diagnosis (n ¼ 700), if they had
<180 days of follow-up (n ¼ 935), if they had an incom-
plete baseline medical history or demographic or staging
information (n ¼ 10), if they had no information on for-
mer versus current smoking status at diagnosis (n ¼ 65),
or if they were light smokers who smoked10 pack-years
(n¼ 250). The final sample size for the analysis was 4200
patients. This included 618 never smokers (15%), 1483
current smokers (35%), 380 former smokers who quit 1
to 12 months before diagnosis (9%), and 1719 former
smokers who quit>12 months before diagnosis (41%).
Table 1 contains the descriptive statistics, overall
and by smoking status category. Half of the participants
were men, 85% were white, and the average age was 64
years. With respect to disease stage, 28% were diagnosed
with stage I or II disease, 27% were diagnosed with stage
III disease, and 45%were diagnosed with stage IV disease.
Greater than 50% of participants were diagnosed with ad-
enocarcinoma (58%), 25% were diagnosed with squa-
mous cell carcinoma, and the remaining 17% were
diagnosed with another histologic type. Approximately
50% of participants had a Charlson comorbidity score of
0 (51%). Close to 66% of participants had received radia-
tion treatment or drug therapy (64% and 65%, respec-
tively), and 34% underwent surgical resection. These
descriptive statistics demonstrate that this cohort is repre-
sentative of the larger population of patients with NSCLC
in the United States.
Survival information is presented in Table 2, and
survival plots are presented in Figures 1, 2, and 3. Among
patients with stage I and II disease, the median survival
has not yet been reached for most smoker groups, and the
2-year survival estimates ranged from 72% (current smok-
ers) to 93% (never smokers). Among the patients with
stage III disease, the median survival ranged from 20.1
months (current smokers) to 37.3 months (never smok-
ers), and the 2-year survival estimates ranged from 41%
(current smokers) to 66% (never smokers). Among the
patients with stage IV disease, the median survival ranged
from 6.7 months (current smokers) to 19.6 months (never
smokers), and the 2-year survival estimates ranged from
15% (current smokers) to 40% (never smokers).
Results from the Cox proportional hazards models
are presented in Table 3, which lists the variables that
were included in the model. The variables age and
NCCN site were included in all models, radiation treat-
ment and resection status were included in the stage I/II
and stage III models, drug therapy and performance status
were included in the stage III and stage IV models, and
histology was included only in the stage I/II model.
Among patients with stage I and II disease, never smokers
had a significantly lower hazard for all-cause mortality
compared with current smokers (HR, 0.47; 95% CI,
0.26-0.85). The results were not statistically significant
for former smokers who quit 1 to 12 months before diag-
nosis (HR, 0.80; 95% CI, 0.51-1.24) and former smokers
who quit >12 months before diagnosis (HR, 0.84; 95%
CI, 0.65-1.08). Among patients with stage III disease, the
results were similar: Never smokers had a significantly
lower mortality (HR, 0.51; 95% CI, 0.38-0.68), and for-
mer smokers had a nonsignificantly lower mortality (for-
mer smokers 1-12 months before diagnosis: HR, 0.79;
95% CI, 0.59-1.07; former smokers >12 months before
diagnosis: HR, 0.85; 95%CI, 0.70-1.03).
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TABLE 1. Baseline Characteristics of Participants in the Non–small Cell Lung Cancer Database Project
According to Smoking Status












Men 212 (34) 781 (53) 189 (50) 918 (53) 2100 (50)
Caucasians 472 (76) 1248 (84) 312 (82) 1534 (89) 3566 (85)
Age at Diagnosis:
MeanSD, y
61.313.1 61.010 62.19.4 68.09.4 64.010.8
Disease stage
I and II 123 (20) 406 (27) 101 (27) 565 (33) 1195 (28)
III 149 (24) 401 (27) 99 (26) 468 (27) 1117 (27)
IV 346 (56) 676 (46) 180 (47) 686 (40) 1888 (45)
Histology
Squamous cell 40 (6) 431 (29) 105 (28) 471 (27) 1047 (25)
Adenocarcinoma
NOS and BAC 504 (82) 756 (51) 193 (51) 967 (56) 2420 (58)
Other 74 (12) 296 (20) 82 (22) 281 (16) 733 (17)
Charlson Comorbidity score
0 482 (78) 686 (46) 195 (51) 763 (44) 2126 (51)
1 136 (23) 797 (54) 185 (49) 956 (56) 2074 (49)
Drug therapy
Yes 422 (68) 987 (67) 239 (63) 1089 (63) 2737 (65)
No 259 (42) 436 (29) 123 (32) 679 (39) 1463 (35)
Resective surgery
Yes 182 (29) 479 (32) 132 (35) 614 (36) 1407 (34)
No 436 (71) 1004 (68) 248 (65) 1105 (64) 2793 (67)
Abbreviations: BAC, bronchioloalveolar carcinoma; NOS, not otherwise specified; SD, standard deviation.
a This analysis excluded patients who had 10 pack-years of smoking.
TABLE 2. Number of Deaths, Censored Observations, Median, and Two-Year Survival According to Smoking













Stage I and II, n ¼ 1195
Current smokersa 406 116 290 (71.4) 46.9 72.4 [66.9-77]
Former smokers
1-12 moa 101 26 75 (74.3) NAb 80 [70-87]
12 moa 565 146 419 (74.2) NAb 75.5 [71.1-79.3]
Never smokers 123 13 110 (89.4) NAb 93.4 [86.6-98.9]
Stage III, n ¼ 1117
Current smokersa 401 240 161 (40.2) 20.1 40.6 [35.3-46]
Former smokers
1-12 moa 99 59 40 (40.4) 20.2 45.2 [34.4-55.4]
12 moa 468 253 215 (45.9) 22.5 49.2 [44.2-54]
Never smokers 149 65 84 (56.4) 37.3 66.4 [57.5-73.9]
Stage IV, n ¼ 1888
Current smokersa 676 570 106 (15.7) 6.7 15.3 [12.5-18.4]
Former smokers
1-12 moa 180 151 29 (16.1) 7.2 19.6 [13.9-26]
12 moa 686 568 118 (17.2) 8.5 19.7 [16.7-23]
Never smokers 346 219 127 (36.7) 19.6 40.4 [34.7-45.9]
Abbreviations: CI, confidence interval; NA, not available.
a This analysis excluded patients who had 10 pack-years of smoking.
bMedian survival was not yet reached in patients with stage I and II disease.
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Among patients with stage IV disease, there was
a significant interaction between smoking status and age
(P¼ .02). Table 3 includes HRs for various ages using the
model coefficient estimates to calculate HRs and 95%
CIs. In general, among younger patients, former smokers
who quit>12months before diagnosis and never smokers
had a significantly lower risk of death compared with cur-
rent smokers. With increasing age, the benefits of being a
former smoker >12 months before diagnosis or a never
smoker diminished, and former smokers who quit >12
months before diagnosis lost the beneficial effect at a faster
pace than never smokers. Smoking had no effect on sur-
vival among patients aged85 years.
DISCUSSION
The results from our analysis of patients in the NCCN
database, which is 1 of the largest cohorts of patients with
NSCLC, suggest that individuals who were smoking at the
time of diagnosis had worse survival compared with never
smokers. The results for patients with stage IV disease sug-
gest that, among younger individuals, current smokers had
worse survival compared with both former smokers who
had quit >12 months before diagnosis and never smokers;
however, as age increased, the benefits of being a former
smoker as well as a never smoker decreased.
Previous research suggests that never smokers and
smokers who quit smoking more than 1 year in advance of
diagnosis have a better survival rate, but most of the signifi-
cant differences have been observed among patients with
early stage NSCLC. In their sample of 543 patients with
early stage NSCLC, Zhou and colleagues reported that
never smokers had half the risk of dying and that former
smokers who quit 9 years before diagnosis had a >30%
reduced risk of dying compared with current smokers.17
Nia and colleagues reported a similar reduced risk among
never smokers and former smokers in their study of 311
patients who underwent curative resection for NSCLC.18
Ebbert and coauthors, in their sample of 4618 patients
with NSCLC, observed that only women with NSCLC
who were former smokers had a reduced risk of dying com-
pared with current smokers; however, all patients in that
study who were never smokers had a lower risk of dying
compared with current smokers.19 In another study of
patients with NSCLC, never smokers had a significant sur-
vival advantage over smokers only among those with stage I
NSCLC, and never smokers with stage II or III disease
Figure 1. This is a Kaplan-Meier survival plot for patients with
stage I and II non–small cell lung cancer according to smok-
ing status at diagnosis
Figure 2. This is a Kaplan-Meier survival plot for patients with
stage III non–small cell lung cancer according to smoking sta-
tus at diagnosis.
Figure 3. This is a Kaplan-Meier survival plot for patients with
stage IV non–small cell lung cancer according to smoking sta-
tus at diagnosis.
Smoking and Survival in NSCLC Patients/Ferketich et al
Cancer February 15, 2013 851
experienced a nonsignificant reduced risk of dying.20 In
contrast, Tammemagi and colleagues observed no differ-
ence according to disease stage in patients with NSCLC; all
never smokers in their study experienced a reduced risk of
dying compared with current smokers.21 Our findings
among patients with early stage NSCLC are consistent
with previous studies, in that we observed improved sur-
vival among never smokers; however, we also noted that
younger never smokers and former smokers with late-stage
disease had a survival advantage over current smokers.
Former smokers who quit within 1 year of diagnosis
had a nonsignificant reduction in mortality compared with
current smokers. Zhou and colleagues reported a similar
nonsignificant reduction in the risk of dying among former
smokers who quit close to diagnosis.17 Other studies have
reported significant differences between recent quitters and
current smokers with respect to survival among patients
with NSCLC. Nia and coauthors concluded that patients
with early stage NSCLC who quit between diagnosis and
surgery were significantly less likely to die than current
smokers.18 Because smoking status was assessed only once
for patients in the NCCN database project, we were not
able to include individuals who quit at diagnosis in our
‘‘former smoker for 1 to 12months’’ group.
We are unaware of other studies reporting a similar
interaction between age and smoking status with regard
to the survival of patients with NSCLC. In our current
study, this interaction was significant only for patients
with stage IV disease. It is possible that, because we had a
larger sample size of patients with stage IV disease, we
had more power to detect this interaction in this group
compared with the other stage groups. Smoking may be a
stronger risk factor for death among younger individuals
compared with older individuals. There is at least 1 report
demonstrating such an interaction on all-cause mortality
in the general population in the United States. In a longi-
tudinal study of 4916 American men and women, current
smoking was a significant predictor of mortality in the in
the groups ages 60 to 69 years and 70 to 79 years, but
not in the group aged 80 years.22
The strengths of this study include the large overall
sample size, which allowed us to examine the association
between smoking and survival according to disease stage.
A second strength of this study is the representative sam-
ple of patients in the NCCN database. The clinical sites
are located in 8 states throughout the United States. Thus,
regional differences in patient characteristics are
accounted for in the analysis.
Limitations of this study include those that are com-
mon in research that relies on the use of a database. First,
smoking status was only measured at diagnosis; thus, we
could not evaluate the effect of quitting smoking after diag-
nosis on survival. Second, detailed information on smoking
history was not obtained. A third limitation relates to the
sample size for former smokers who quit within 1 year of
TABLE 3. Results From Cox Proportional Hazards
Regression Models According to Disease Stage
Variable HR (95% CI)a
Stage I and II, n ¼ 1195
Current smokers 1.00
Former smokers
1-12 mo 0.80 (0.51-1.24)
>12 mo 0.84 (0.65-1.08)
Never smokers 0.47 (0.26-0.85)
Stage III, n ¼ 1117
Current smokers 1.00
Former smokers
1-12 mo 0.79 (0.59-1.07)
>12 mo 0.85 (0.70-1.03)
Never smokers 0.51 (0.38-0.68)
Stage IV, n ¼ 1888
Estimates for patients aged 45 y
Current smokers 1.00
Former smokers
1-12 mo 1.09 (0.77-1.55)
>12 mo 0.70 (0.53-0.91)
Never smokers 0.39 (0.30-0.51)
Estimates for patients aged 55 y
Current smokers 1.00
Former smokers
1-12 mo 1.02 (0.83-1.26)
>12 mo 0.78 (0.66-0.93)
Never smokers 0.48 (0.40-0.57)
Estimates for patients aged 65 y
Current smokers 1.00
Never smokers 0.95 (0.77-1.16)
Former smokers
1-12 mo 0.88 (0.77-1.00)
>12 mo 0.58 (0.49-0.69)
Estimates for patients aged 75 y
Current smokers 1.00
Never smokers 0.88 (0.63-1.24)
Former smokers
1-12 mo 0.99 (0.81-1.20)
>12 mo 0.70 (0.54-0.92)
Estimates for patients aged 85 y
Current smokers 1.00
Never smokers 0.82 (0.49-1.38)
Former smokers
1-12 mo 1.11 (0.82-1.49)
>12 mo 0.86 (0.58-1.26)
Abbreviations: CI, confidence interval; HR, hazard ratio.
a The stage I and II model was adjusted for National Comprehensive Can-
cer Network (NCCN) institution, age at diagnosis, histology, resection sta-
tus, and receipt of radiation; the latter 2 variables were stratified because
of nonproportionality. The stage III model was adjusted for NCCN institu-
tion, age at diagnosis, receipt of radiation, resection status, receipt of drug
therapy, and ECOG performance status; the latter 3 variables were strati-
fied because of nonproportionality. The stage IV model was adjusted for
NCCN institution, age at diagnosis, receipt of drug therapy, and Eastern
Cooperative Oncology Group performance status; the latter 2 variables
were stratified because of nonproportionality.
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diagnosis. This group comprised relatively few study partic-
ipants (n ¼ 380); thus, the nonsignificant results observed
may be attributed to this smaller sample size. A fourth limi-
tation relates to the finding that we did not have informa-
tion on socioeconomic status, which is strongly associated
with smoking status. Because we relied on medical chart
data, it was not possible to consistently collect information
on income, occupation, or education, all of which may be
used as proxies for socioeconomic status. Finally, although
data regarding the molecular characterization of these
patients are currently being collected, for most of these
patients, the status of EGFR and v-Ki-ras2 Kirsten rat sar-
coma viral oncogene homolog (K-ras) mutations, echino-
derm microtubule associated protein-like 4 (EML4-ALK)
translocations, and other changes is not known. The impact
of these distinct molecular subtypes of lung cancer is likely
to be greatest in patients with recurrent or metastatic dis-
ease, in that treatment with molecular-targeted agents
against EGFR or ALK (erlotinib and crizotinib, respec-
tively) is not typically done outside of a clinical trial in
patients with stage I, II, or III disease.
In conclusion, the results from this analysis of 4200
patients with NSCLC suggest that individuals who were
smoking at the time of diagnosis had worse survival com-
pared with never smokers. Among younger patients with
stage IV NSCLC, current smokers also had worse survival
compared with former smokers who quit >12 months
before diagnosis. Although some of these differences prob-
ably are related to tumor biology, it is prudent to recom-
mend that all smokers, even those with a high pack-year
history of smoking, should be encouraged to quit smoking
to improve their potential survival if they are diagnosed
with NSCLC. Younger patients who were diagnosed with
late-stage cancer and who quit smoking >12 months
before diagnosis experienced a significantly decreased risk
of dying, and most smokers who quit within 1 year of diag-
nosis had a lower, albeit nonsignificant, risk of dying com-
pared with current smokers at the time of diagnosis.
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